BriaCell Therapeutics Corp. (BCTXZ)
$0.20-4.76%Close
BUYCRISIS · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $376,748
- Beta
- 1.54
- P/E (TTM)
- -0.31
- Short % float
- 0.35%
- Days to cover
- 1.0
- SI change
- +0.0%
- 1W
- -28.57%
- 1M
- +42.86%
- vs SPY 1W
- -28.43%
- vs SPY 1M
- +40.35%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 9
- VALUE
- 8
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-88.7%
REV YoY-
ROE-147.9%
EPS YoY-
ROA-113.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.31
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.13
P/FCF-
EV/EBITDA-0.81
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO7.07
ND/EBITDA-
BETA1.54
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on BCTXZ?
- LOPJLB’s latest quantitative signal on BriaCell Therapeutics Corp. Warrant (BCTXZ) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is BCTXZ in?
- BriaCell Therapeutics Corp. Warrant (BCTXZ) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does BriaCell Therapeutics Corp. Warrant (BCTXZ) do?
- BriaCell Therapeutics Corp., a biotechnology company based in West Vancouver, Canada, is intensely focused on immuno-oncology, dedicated to engineering novel immunotherapies for cancer treatment. Its flagship compound, Bria-IMT, is a whole-cell cancer vaccine presently in Phase I/IIa clinical development, where it's being evaluated in conjunction with the investigational immunotherapy retifanli…